A phase II clinical trial of diaziquone (AZQ) in the treatment of patients with recurrent leiomyosarcoma of the uterus. A Gynecologic Oncology Group study.
Based upon the activity observed in this trial, there does not appear to be a significant role for AZQ as a salvage agent for leiomyosarcoma of the uterus at the dose and schedule tested.
Slayton
R E
RE
Department of Medicine, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.
Blessing
J A
JA
Look
K
K
Anderson
B
B
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001388:Aziridines / Q000009:adverse effects / Q000627:therapeutic use*; D016227:Benzoquinones / Q000009:adverse effects / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007890:Leiomyosarcoma / Q000188:drug therapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D014594:Uterine Neoplasms / Q000188:drug therapy*
D000970:Antineoplastic Agents; D001388:Aziridines; D016227:Benzoquinones; C029108:diaziquone